J Control Release. 2025 Oct 10:386:114126. doi: 10.1016/j.jconrel.2025.114126. Epub 2025 Aug 14. A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle Abstract Ionizable cationic lipid is critical for construction of lipid nanoparticles (LNPs) for mRNA delivery. Here, we reported the rational design and evaluation of FS01, a novel ionizable cationic lipid incorporating an ortho-butylphenyl-modified hydrophobic tail into a squaramide-based lipid headgroup architecture. Molecular dynamics simulations revealed that FS01 enhances mRNA stability through π-π stacking interactions between its aromatic tail and nucleobases aromatic rings, alongside hydrogen bonding via the squaramide headgroup. FS01-LNPs demonstrated smaller particle sizes (∼ 70 nm), high encapsulation efficiency (> 90 %), and superior mRNA delivery performance across intramuscular, subcutaneous, and intravenous routes in mice compared to FDA-approved lipids (Dlin-MC3-DMA, SM-102, ALC-0315). In prophylactic vaccine models (Varicella-zoster virus and Hepatitis B virus), FS01-LNP formulations elicited robust antigen-specific antibodies, memory B cells, and Th1-biased T cell responses, outperforming benchmark LNPs. Further, transcriptomic profiling and safety assessments demonstrated that FS01-LNP induced a well-balanced innate immune activation with minimal inflammation and liver toxicity, contrasting with the pronounced reactogenicity of Dlin-MC3-DMA and ALC-0315 LNPs. These findings highlighted FS01 as a promising ionizable lipid candidate for mRNA therapeutics, offering enhanced delivery efficiency, immunogenicity, and safety, with potential applications extending beyond vaccines to gene editing and protein replacement therapies. Keywords: Immunogenicity; Inflammation; Ionizable cationic lipid; Lipid nanoparticle; Reactogenicity; Π-π stacking interaction. Product: lipids for LNP

Bioconjug Chem. 2026 Jan 21;37(1):160-168. doi: 10.1021/acs.bioconjchem.5c00554. Epub 2026 Jan 10. "Zip-to-Cytosol": Glutathione-Cleavable Fluorinated Polyplexes Deliver siRNA at Single-Digit Nanomolar Dose with >90% Gene Silencing Abstract A fluorinated, disulfide-cross-linked polyplex platform (PFND) was developed for safe and potent cytosolic delivery of siRNA. Branched PEI (25 kDa) was first perfluoro-acylated to yield a membrane-zipper PF backbone, followed by orthogonal installation of azide (PF-N3) and strained alkyne (PF-DBCO) handles that undergo in situ copper-free click cross-linking in the presence of siRNA. The resulting 60 nm polyplexes (PDI < 0.1, ζ potential of approximately +22 mV) are stable in 10 mg mL-1 heparin (<5% siRNA leakage) yet quantitatively disassemble within 60 min in 10 mM glutathione, liberating the siRNA payloads. Compared with the commercial gold standard of Lipofectamine 3000, PFND delivers 2- to 3-fold more Cy5-siRNA into HeLa, HepG2, and MDA-MB-468 cells without detectable hemolysis or cytotoxicity. Consequently, 10 nM siGAPDH delivered by PFND silences approximately 93-98% of GAPDH mRNA across the three lines, remarkably outperforming gold-standard transfection reagents. The proposed reversible "locked-outside/labile-inside" design reconciles extracellular stability with rapid intracellular release, offering a valid tool for utilities of high-throughput siRNA screening or subject to be developed further for potential clinical translation of RNAi-based therapeutics. Product: NHS-PEG4-N3 Various Kingds And Grades Of Such Monodispersed Are Readily Avaliable| SINOPEG

Join Us at CPHI China 2026! SINOPEG's booth no. W4F66 Exciting news! CPHI China 2026 is just around the corner, taking place June 16–18 at the Shanghai New International Expo Centre. SINOPEG will be showcasing cutting-edge drug delivery system (DDS) solutions at Booth W4F66. As your trusted partner in specialty chemicals and advanced drug delivery systems, we’re eager to share innovations that drive industry progress. Why visit us? Explore our latest portfolio of PEG derivatives, lipids, and custom synthesis services Discuss tailored solutions for your R&D and manufacturing challenges Connect face-to-face with our technical experts We warmly welcome friends, partners, and industry peers from around the globe to drop by! Let’s collaborate to shape the future of pharma. Dates: June 16–18, 2026 Venue: Shanghai New International Expo Centre Our Booth: W4F66 (Hall W4) Ready to meet? Simply stop by!

Join Us at TIDES USA 2026 in Hynes Convention Center! Mark your calendars! TIDES USA 2026—the premier event for oligonucleotide and peptide therapeutics—is coming to Boston, MA, on May 11-14, 2026. Visit Sinopeg at Booth #1010 to explore cutting-edge solutions in: Custom PEG Derivatives (mPEG, heterobifunctional PEGs, branched PEGs) Lipid Nanoparticles (LNPs) & Lipidoids for nucleic acid delivery Innovative Linker Technologies & ADC Payloads Why Stop By? Discuss your formulation challenges with our PEGylation experts Discover high-purity excipients for mRNA, siRNA, and peptide therapies Learn how our GMP-grade materials accelerate preclinical-to-commercial transitions Spotlight Case Study: Ask us about our role in developing temperature-stable LNP formulations for a global mRNA vaccine partner! Schedule a 1:1 Meeting: Avoid the crowds—reserve your private session today: sales@sinopeg.com Can't attend? Explore our solutions online: http://www.sinopeg.com Let's shape the future of oligonucleotide and peptide therapeutics together! See you at #1010. #TIDES2026 DrugDiscovery #LNPs #mRNA #PeptideTherapeutics #BiotechInnovation

Spring brings another good news! Following the European patent allowance for cationic lipids in February 2026, our patent portfolio has achieved another milestone. In April 2026, several cationic lipid products independently developed by Sinopeg—including DHA-1, SNP24-1, SNP25-1, and SNP26-1—successfully received U.S. patent allowance, protected in the form of a Markush formula. With this, the DHA-1 series cationic lipids have now secured patent coverage in the three core markets of China, Europe, and the United States, establishing a global intellectual property moat for this key excipient of LNP delivery systems. Patent Title: Cationic Lipid, Liposome Containing Cationic Lipid, and Nucleic-Acid Pharmaceutical Composition Containing Liposome and Formulation and Application Thereof Patent Application No.: 18/269,728 Applicant: Xiamen Sinopeg Biotech Co., Ltd. Source: Notice of Allowance from the USPTO (screenshot) Patent Breakthrough: Comprehensive Coverage from China to Europe and the U.S. DHA-1, SNP24-1, SNP25-1, SNP26-1, and others are cationic lipids independently developed by Sinopeg. They feature high biocompatibility and high transfection efficiency, effectively bypassing existing patent restrictions and providing a reliable, localized alternative for the LNP delivery field. In terms of IP strategy, the patent journey for the DHA-1 series has been solid and methodical: September 2022: Granted Chinese patent (priority application). October 2023: Granted patent for PCT national phase entry in China. February 2026: Granted European patent, achieving full coverage in China and Europe. April 2026: Granted U.S. patent, protected in Markush formula form. Thus, the DHA-1 series cationic lipids now hold patent protection in all three major markets—China, Europe, and the U.S.—providing a strong legal foundation for compliant commercialization and global business expansion. Beyond patent coverage, DHA-1 also leads in regulatory compliance: it has successfully completed CDE pharmaceutical excipient filing in China (Filing No. F20230000445) and has submitted a U.S. FDA DMF (Filing No. 039452). Customers can directly reference Sinopeg's filed dossiers in both China and the U.S., significantly reducing submission preparation time and accelerating project progress. Markush Formula Allowance: Broader Protection, Stronger Barrier What is a Markush formula allowance, and how is it different from a standard compound patent? Simply put, the Markush formula is one of the most valuable forms of patent protection in the pharmaceutical compound field. It uses a "generic formula" approach, covering a class of compounds that share a common structure and similar properties, rather than protecting only a single structure. For this series of cationic lipids, this means: Broader protection – The patent covers not only the dozens of specific structures exemplified (including DHA-1, SNP24-1, SNP25-1, SNP26-1) but also other cationic lipid structures sharing the same core ...

As we prepare to welcome a season of strength, speed, and success, our team will be taking a short break to celebrate the Chinese New Year with our loved ones. Holiday Notice: We will be closed from February 15 to February 23. Normal business operations will resume on February 24. During this period, if you have any urgent inquiries or project needs, please feel free to: Leave us a message via our website: www.sinopeg.com Or email us at: sales@sinopeg.com We’ll get back to you promptly upon our return. Wishing you and your family a joyful, prosperous, and horse-powered New Year! #ChineseNewYear #YearOfTheHorse #SpringFestival #HolidayNotice #GlobalBusiness #Sinopeg #ClientCare #NewYear2026